Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

according to a presenter at the American Academy of Dermatology Annual Meeting Rocatinlimab (Amgen, Kyowa Kirin) is a potential first and only T-cell rebalancing therapy that targets the OX40R ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio ...

Please provide your email address to receive an email when new articles are posted on . Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s ...

Amgen and UCB finally have FDA approval for ... At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...

Story Feb. 4 - Kyowa Kirin: The Japanese pharma is letting go ... shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and ...